The upcoming announcement for the 2024 Medicare Part B premiums raises questions of a possible increase due to coverage of a new, expensive Alzheimer’s drug, Leqembi, mirroring the situation in 2022 with a different Alzheimer’s drug, Aduhelm. Although Leqembi is not a cure and is only approved for certain patients, it is the first drug to clinically slow down the disease’s progression.

First AI-Powered Ransomware Can Automate Attacks With Unprecedented Speed – HotHardware
First AI-Powered Ransomware Can Automate Attacks With Unprecedented Speed HotHardware